A widow recounts how her husband’s prescribed medication for Parkinson’s disease transformed him into a compulsive sex addict overnight, demanding intimacy multiple times daily and amassing pornography collections.
Jane Ryde’s Heartbreaking Account
Jane Ryde describes her spouse’s sudden behavioral shift after starting Pramipexole, a dopamine agonist that eased his Parkinson’s symptoms but unleashed severe impulse control issues. “He changed overnight into someone I didn’t recognise,” she states. “He was a hard-working man and he just became a sex addict—very compulsive behaviour collecting porn snippets and pornography.”
Ryde notes he stayed up until the early hours browsing explicit content, from professional videos to homemade clips, which she discovered in his history. She shielded their adult children from the ordeal, acting as a buffer while documenting everything in a diary amid escalating arguments.
Consultants dismissed the conduct as unacceptable without further action, despite no prominent warnings on the drug leaflets labeling such disorders as “uncommon,” affecting less than 1% of users. Ryde received no prior alerts from doctors.
Discrepancies in Side Effect Data
A 2010 study, partially funded by the manufacturer, estimates impulse control disorders impact about 17% of patients—far higher than leaflet claims, which remain unchanged. Pramipexole, produced by Boehringer Ingelheim, belongs to a class of eight dopamine agonists prescribed over 1.5 million times annually in the UK for Parkinson’s, restless legs syndrome, pituitary tumors, and certain mental health issues.
Ryde, managing her husband’s regimen of up to 12 daily tablets, refrained from altering it herself. “I’m not a pharmacologist,” she explains. The ordeal forced emotional distance for self-preservation. “If drug manufacturers knew about these problems, they should have acted sooner,” she asserts. “One in six is not an uncommon side-effect—it’s scandalous and irresponsible.”
Her husband passed away in 2021, leaving few positive memories amid the disease’s toll.
Manufacturer and Regulatory Responses
Boehringer Ingelheim affirms compliance with international guidelines on side-effect frequencies and acknowledges reports of impulse control disorders in Parkinson’s and restless legs patients. “We recognise their courage in talking about these difficult issues and raising awareness,” the company states.
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) announces a comprehensive review of all dopamine agonists to address inconsistencies in leaflet warnings and implement corrections.
Parallel Tragic Case
This revelation echoes another incident where solicitor Andrew Taylor embezzled over £600,000 from vulnerable elderly clients, squandering it on sex workers, webcams, and antiques—blamed on Pramipexole. The fallout contributed to Taylor and his son’s suicides, with courts linking his actions to the medication’s impulsive effects.
